Thymoglobulin (ATG) Dose Finding Study

Stopped early · Phase 1/Phase 2

Conditions studied: Graft vs Host Disease

In brief

Primary Objective: * To determine the response and toxicity rate at day 56 of two different dose levels of thymoglobulin (ATG) \[anti-thymocyte globulin (rabbit)\] as a treatment of steroid-refractory acute graft versus host disease (aGVHD). Secondary Objectives: * To evaluate the response rate at day 28. * To evaluate the overall survival and non-relapse mortality at 6 months. * To determine the toxicity profile of thymoglobulin when used for the treatment of steroid-refractory aGVHD in each of two dose schedules. * To characterize the pharmacokinetic profile of thymoglobulin in each of two dose schedules. * To analyze biomarkers of cellular drug effect by quantifying T-cell apoptosis in aims of finding the minimal effective dose. * To determine immune-reconstitution after administration of thymoglobulin to patients with steroid-refractory aGVHD for each dose schedule.

Key facts

Study ID

NCT00409695

Run by

M.D. Anderson Cancer Center

People needed

1

Starts

2006-12-01

Expected to finish

2007-08-01

Last updated by the study team

2012-01-23

Who can join

Age: any. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Patients who underwent their first allogeneic transplant for any malignancy and with any cell (bone marrow, peripheral stem cell, cord blood) or donor (matched or mismatched related or unrelated) source.
• Biopsy-proven, grade II-IV aGVHD following allogeneic hematopoietic stem cell transplantation (HSCT) of any source (bone marrow, peripheral blood or cord blood stem cells). Enrollment may be started prior to results of biopsy in cases of high clinical suspicion for aGVHD.
• Early steroid-refractory aGVHD. This is defined as any NR or PD after a minimum of 3 days and not more than 1 week of 1 mg/kg/day of methylprednisolone.
• Ability to sign informed consent.
• Ability to return for clinical follow-up as specified in the protocol.
• Inability to taper as defined by patients on < or = 1 mg/kg/day of methylprednisolone but unable to further taper without resultant increase of acute GVHD stage.
• Patients with a reflare of a GVHD defined as worsening of 1 stage of acute GVHD in a patient who initially responded.

You may not qualify if…

• Relapsed malignancy.
• Acute GVHD as a result of a second or subsequent transplant or donor lymphocyte infusion (DLI).
• Active, uncontrolled infection.
• Patients who have received any second-line of immunosuppressive treatment for GVHD beyond corticosteroids and calcineurin inhibitors. Topical steroids, oral budesonide and extracorporeal photochemotherapy started at the time of steroids are allowed.
• Life-threatening infusion reaction or hypersensitivity to any formulation of ATG in the past.
• Patients who are pregnant or are breast feeding.

Where it is running

• U.T. M.D. Anderson Cancer Center — Houston, Texas, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.